At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Multicenter Randomized Two-arm Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Pretreated Adult Patients With EGFR Wild-type ALK Rearrangement Negative Advanced/Metastatic Non-small Cell Lung Cancer
In Brief
A Phase 2 clinical trial evaluating Capmatinib, Spartalizumab, and 1 other intervention for Carcinoma, Non-Small-Cell Lung. Completed, enrolled 18 participants across 8 sites in 6 countries.
Detailed Summary
The purpose of this trial was to evaluate the safety and efficacy of capmatinib in combination with spartalizumab in adult participants with epidermal growth factor receptor (EGFR) wild type (for exon 19 deletions and exon 21 L858R substitution mutations), anaplastic lymphoma kinase (ALK) rearrangement negative in locally advanced (stage IIIB, not eligible for definitive chemo-radiation) or metastatic (stage IV) Non-small cell lung cancer (NSCLC) after failure of platinum doublet and checkpoint inhibitor treatment.
Study Details
Timeline
Interventions
Capmatinib 400 mg (tablets) orally taken twice daily
Spartalizumab 400 mg via intravenous infusion once every 28 days
Docetaxel 75mg/m2 i.v. following local guidelines as per standard of care and product labels once every 21 days